The use of anti-EGFR antibodies in the treatment of metastatic CRC, first used in the 3rd line, and then as part of combination treatments in 1st and 2nd line systemic chemotherapies, has clearly improved efficacy [22]. Here, EGFR is linked to colorectal carcinoma.